Sylvester Comprehensive Cancer Center | Strategic Alliance Partners

Connect with us:

Latest from Sylvester Comprehensive Cancer Center


Taylor Provides Insight Into Pirtobrutinib Resistance in CLL

May 23, 2022

Dr Taylor discusses the significance of BTK inhibition in chronic lymphocytic leukemia, describes the key objectives of, and methods used, for the genomic analyses performed by his team, underscores the clinical significance of the data yielded from this research, and outlines where future efforts will focus.

New Research Highlights Racial Disparities in Genomic Profiling

May 23, 2022

A new study by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine has found that Black women with metastatic breast cancer were less likely to have tumors with treatable genetic variations than white and Asian women.

Renowned Robotic Surgeon First to Use New 3D Kidney Model

April 29, 2022

Renowned robotic urologic oncology surgeon Dipen J. Parekh, MD, was the first in the nation to test a new preoperative surgical rehearsal technology recently approved by the FDA for all genitourinary conditions.

Sylvester Joins Forces with College of Engineering to Cure Cancer

April 11, 2022

Researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine have joined forces with the University of Miami College of Engineering for a collaborative initiative to develop and deploy innovative technologies for early detection, diagnosis, and treatment of cancer.

Genomic Analyses Shed Light on Mechanisms of Resistance to Noncovalent BTK Inhibitors in Relapsed/Refractory CLL

April 07, 2022

Justin W. Taylor, MD, discusses the significance of BTK inhibition in the treatment of patients with CLL, the genomic analyses conducted in those enrolled to BRUIN who received pirtobrutinib, and the significance of the data yielded from this research.

Dr. Dorothy Graves Joins Sylvester as Assistant Vice President and Associate Director for Administration

March 21, 2022

Dorothy Graves, PhD, said she admired Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine years prior to being appointed Sylvester’s assistant vice president and associate director for administration in early 2022.

Venetoclax/Selinexor Combo Shows Efficacy in Relapsed/Refractory Multiple Myeloma With t(11;14)

December 13, 2021

Selinexor combined with venetoclax demonstrated efficacy and tolerability in heavily pretreated relapsed/refractory multiple myeloma cell lines with t(11;14), according to small study results that were presented during the 2021 ASH Annual Meeting.

Pirtobrutinib Exhibits Promising Efficacy in Heavily Pretreated MCL and Other Non-Hodgkin Lymphomas

September 03, 2021

Pirtobrutinib elicited encouraging responses across all dose levels in patients with mantle cell lymphoma and other non-Hodgkin lymphoma who previously received all classes of available therapy, with benefit observed independent of prior therapy received, according to data from the phase 1/2 BRUIN study.

Sekeres Previews Potential Combination Strategies in HR-MDS

August 30, 2021

Dr. Sekeres discusses the current unmet needs of patients with higher-risk myelodysplastic syndromes receiving hypomethylating agents, the potential utility of novel combinations in development, and the incorporation of other end points beyond overall survival in clinical trials.